Glenmark molecule enters human trials;stk up

MUMBAI: Glenmark Pharmaceuticals has announced that its novel molecule 'GRC 17536' for pain and respiratory is entering human trials. “The addressable market for Asthma/COPD is approximately USD 30 billion while the market for osteoarthritis and neuropathic pain is approximately USD 10 billion,” the company said in a statement.

The stock was at Rs 291, up 0.81 per cent on the NSE. The stock moved between a high of Rs 296 and low of Rs 285 in trade so far.